Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

RAD Appointments Sep/Oct 07

This article was originally published in RAJ Devices

Executive Summary

Sheldon Bradshaw has left his job as associate general counsel/ chief counsel of the US Food and Drug Administration (FDA) to join law firm Hunton & Williams. He will be a partner of the firm and co-chair of its Food and Drug Practice. Jeffrey Senger, the current deputy associate general counsel, has become acting associate general counsel until a permanent replacement is appointed. The US Medical Device Manufacturers Association (MDMA) has appointed Thomas C Novelli to be its new director of federal affairs. Mr Novelli previously served on the US Senate Committee on Finance, working on drug and device safety and approval, reimbursement and fraud and abuse within the Medicare and Medicaid programmes, among other things.

You may also be interested in...



Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease

Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.

Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative

Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.

Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says

The statement, which is part of a final rule on the 340B administrative dispute resolution process, could facilitate manufacturer efforts to seek repayments from hospitals in such cases.

Latest Headlines
See All
UsernamePublicRestriction

Register

SC094802

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel